Search Result

Results for "

neurological conditions

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (2) Akt (1) Calcium Channel (1) CD28 (1) Cholinesterase (ChE) (3) Dopamine Receptor (1) Drug Derivative (1) Ephrin Receptor (1) ERK (1) mAChR (1) nAChR (2) Thyroid Hormone Receptor (1) TRP Channel (1)
By Research Areas:	Cancer (1) Infection (1) Inflammation/Immunology (2) Metabolic Disease (1) Neurological Disease (20)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-122520

Fentonium bromide	mAChR	Neurological Disease
Fentonium bromide is an anti-ulcerogenic, anticholinergic and antispasmodic agent. Fentonium bromide can be used in the research of neurological conditions, such as unstable bladder .

HY-105365

PD 175069	Calcium Channel	Neurological Disease
PD 175069 is a potent and selective N-type calcium channel antagonist with an IC₅₀ of 0.32 μM. PD 175069 is efficacious in an audiogenic seizure model using DBA/2 mice. PD 175069 can be used for on neurological conditions such as neuropathic pain and stroke .

HY-19073

TS-80 hydrochloride	Others	Neurological Disease
TS-80 hydrochloride is a Mef2 transcriptional activator, and can be used for research of neurologic conditions .

HY-118222

KBR 2822	Cholinesterase (ChE)	Neurological Disease
KBR 2822 is an inhibitor of neurological target esterase (NTE) and has an inhibitory effect on AChE. KBR 2822 can aggravate neurological damage under certain conditions, but does not cause neurological disease when used alone in the absence of direct neurotoxicity or biochemical damage.

HY-108081

GSK-958108	5-HT Receptor	Neurological Disease
GSK-958108 is a highly selective 5-HT1A receptor antagonist. GSK-958108 is commonly used in the study of neurological conditions .

HY-106857A

RA-octil HOE 065	Drug Derivative	Neurological Disease
RA-octil is a derivative related to angiotensin-converting enzyme inhibitors. RA-octil exhibits a memory promoting effect. RA-octil can be used for research on neurological conditions .

HY-119513

Nizofenone	Others	Neurological Disease
Nizofenone is a neuroprotective agent which protects neurons from death following cerebral ischemia or anoxia. Nizofenone can be used in the research of acute neurological conditions, such as stroke .

HY-119677R

Oxypertine (Standard) WIN-18501-2 (Standard)	Others	Neurological Disease
Oxypertine (Standard) is the analytical standard of Oxypertine. This product is intended for research and analytical applications. Oxypertine is a neuroprotective agent. Oxypertine can be used in the research of neurological conditions, such as anxiety and schizophrenia .

HY-179121

AChE-IN-97	Cholinesterase (ChE)	Neurological Disease
AChE-IN-97 is a cholinesterase inhibitor. AChE-IN-97 exhibits AChE and BChE inhibitory activity through molecular docking. AChE-IN-97 can be used for research on neurological conditions .

HY-105690

SAR-115740	TRP Channel	Neurological Disease Inflammation/Immunology
SAR-115740 is a TRPV1 antagonist. SAR-115740 exhibits developmental toxicity in H9 cell experiments. SAR-115740 can be used for research on inflammatory conditions or neurological disorders .

HY-P11244

150D4	Ephrin Receptor	Neurological Disease
150D4 is an efficient, selective, and blood-brain barrier penetrable EphA4 agonist. 150D4 has excitatory activity and neuroprotective effects. 150D4 can be used for research on neurological conditions .

HY-119677

Oxypertine WIN-18501-2	5-HT Receptor Dopamine Receptor	Neurological Disease
Oxypertine (WIN-18501-2) is a neuroprotective agent. Oxypertine shows high affinity for the 5-HT2 and dopamine D2 receptors with K_is of 8.6 nM and 30 nM, respectively. Oxypertine can be used in the research of neurological conditions, such as anxiety and schizophrenia .

HY-110168

NS 9283	nAChR	Neurological Disease
NS9283 is a positive positive allosteric modulator of (α4)₃(β2)₂ nicotinic ACh receptors. NS9283 can be used in a series of neurological conditions such as attention deficit hyperactivity disorder (ADHD), schizophrenia, Parkinson's disease and Alzheimer's disease .

HY-P11130

LQEQ-19 (mouse, rat)	Akt ERK	Neurological Disease
LQEQ-19 (mouse, rat) is a VGF derived peptide that exerts neuroprotective effects. LQEQ-19 (mouse, rat) activates the PI3K/Akt and MEK/ERK signaling pathways by promoting phosphorylation of Akt and ERK1/2. LQEQ-19 (mouse, rat) is commonly used in the study of neurological conditions .

HY-110168R

NS 9283 (Standard)	nAChR	Neurological Disease
NS 9283 (Standard) is the analytical standard of NS 9283. This product is intended for research and analytical applications. NS9283 is a positive positive allosteric modulator of (α4)3(β2)2 nicotinic ACh receptors. NS9283 can be used in a series of neurological conditions such as attention deficit hyperactivity disorder (ADHD), schizophrenia, Parkinson's disease and Alzheimer's disease .

HY-119495

JTP 2942	Thyroid Hormone Receptor	Neurological Disease
JTP 2942 is a thyrotropin-releasing hormone analogue. JTP 2942 can promote the release of Acetylcholine in the hippocampus and frontal cortex of rats. JTP 2942 possesses neuroprotective and cognitive-improving activities. JTP 2942 dose-dependently improves motor and neurological deficits in rat models of chronic focal cerebral ischemia. JTP 2942 can be used for the research of cerebral ischemia, motor neuron diseases, and other related conditions .

HY-P99123A

Anti-Mouse CD28 (LALA-PG) Antibody (D665)	CD28	Neurological Disease Inflammation/Immunology Cancer
Anti-Mouse CD28 (LALA-PG) Antibody (D665) is an anti-mouse CD28 IgG2a monoclonal antibody. Anti-Mouse CD28 (LALA-PG) Antibody (D665) is a chimeric antibody of the original D665 antibody (HY-P990793). Anti-Mouse CD28 (LALA-PG) Antibody (D665) contains the LALA-PG mutation region. Anti-Mouse CD28 Antibody (D665) induces the activation of T cells. Anti-Mouse CD28 Antibody (D665) can be used for research on neurological conditions, inflammation, immunology and cancer, such as Parkinson disease (PD), arthritis and graft-versus-host disease (GVHD).

HY-W540232

4-Methoxyphenyl isothiocyanate 4-Methylphenyl ITC	Cholinesterase (ChE)	Neurological Disease
4-Methoxyphenyl isothiocyanate (4-Methylphenyl ITC) is an antioxidant, with a IC₅₀ value of 1.25 mM for scavenging DPPH radicals. ORAC testing indicates its antioxidant capacity as 11.7 mM TE (indicating that the antioxidant efficacy of this compound is equivalent to 11.7 mmol of Trolox (HY-101445, a standard antioxidant) under the same conditions), and it extends the oxidation process by approximately 9180 seconds in the Briggs–Rauscher reaction. Additionally, 4-Methoxyphenyl isothiocyanate exhibits moderate cholinesterase inhibitory activity, with an inhibition rate of 30.4% against acetylcholinesterase (AChE) and 17.9% against butyrylcholinesterase (BChE). 4-Methoxyphenyl isothiocyanate holds potential for research in the fields of antioxidation and neurological disorders .

HY-W414548

7α,27-Dihydroxycholesterol	Others	Neurological Disease Metabolic Disease
7α,27-Dihydroxycholesterol is an oxysterol characterized by its oxidized side chains and is produced through the hydroxylation of 27-Hydroxycholesterol (27-OHC); it serves as a metabolite of interest in lipidomic analyses of various pathological conditions, including neurological diseases, Smith-Lemli-Opitz syndrome, obesity metabolic syndrome, and diabetes. Notably, levels of 7α,27-di-OHC decrease following lipopolysaccharide activation, and it also functions as a ligand for Epstein-Barr virus-induced gene 2 (EBI2). Additionally, 7α,27-di-OHC exists as a structural isomer of 7α,25-dihydroxycholesterol (7α25-OHC).

Cat. No.	Product Name

HY-L022M

FDA-Approved Drug Library Mini	3,181 compounds
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing. MCE owns a unique collection of 3,181 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. The package of this library is 96-well microplate with peelable foil seal, which makes the screening process easier and faster.

FDA-Approved Drug Library Mini

3,181 compounds

New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.

MCE owns a unique collection of 3,181 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. The package of this library is 96-well microplate with peelable foil seal, which makes the screening process easier and faster.

Cat. No.	Product Name	Target	Research Area

HY-P11244

150D4	Ephrin Receptor	Neurological Disease
150D4 is an efficient, selective, and blood-brain barrier penetrable EphA4 agonist. 150D4 has excitatory activity and neuroprotective effects. 150D4 can be used for research on neurological conditions .

HY-P11130

LQEQ-19 (mouse, rat)	Akt ERK	Neurological Disease
LQEQ-19 (mouse, rat) is a VGF derived peptide that exerts neuroprotective effects. LQEQ-19 (mouse, rat) activates the PI3K/Akt and MEK/ERK signaling pathways by promoting phosphorylation of Akt and ERK1/2. LQEQ-19 (mouse, rat) is commonly used in the study of neurological conditions .

Cat. No.	Product Name	Target	Research Area

HY-P990229

Anti-Rat IgG2b Antibody (RG7/11.1)	Inhibitory Antibodies	Infection Neurological Disease
Anti-Rat IgG2b Antibody (RG7/11.1) is an anti-rat IgG2b monoclonal antibody. Anti-Rat IgG2b Antibody (RG7/11.1) can be used for research on neurological and infection conditions such as temporal lobe epilepsy (TLE). Anti-Rat IgG2b Antibody (RG7/11.1) is often used for the same type control .

HY-P99123A

Anti-Mouse CD28 (LALA-PG) Antibody (D665)	CD28	Neurological Disease Inflammation/Immunology Cancer
Anti-Mouse CD28 (LALA-PG) Antibody (D665) is an anti-mouse CD28 IgG2a monoclonal antibody. Anti-Mouse CD28 (LALA-PG) Antibody (D665) is a chimeric antibody of the original D665 antibody (HY-P990793). Anti-Mouse CD28 (LALA-PG) Antibody (D665) contains the LALA-PG mutation region. Anti-Mouse CD28 Antibody (D665) induces the activation of T cells. Anti-Mouse CD28 Antibody (D665) can be used for research on neurological conditions, inflammation, immunology and cancer, such as Parkinson disease (PD), arthritis and graft-versus-host disease (GVHD).

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.